Logo

People in the News: Mar 18, 2010

Mar 18, 2010
Premium

Traversa Therapeutics has appointed Bharat Chowrira to its board of directors.

Chowrira is currently COO and senior vice president of biopharmaceutical firm Nektar Therapeutics. Before this, he was executive director of worldwide licensing and external research at Merck.

Chowrira joined Merck after its acquisition of RNAi drug shop Sirna Therapeutics, where he served as vice president.

He holds a PhD in microbiology and molecular genetics from the University of Vermont and a JD from the College of Law at the University of Denver.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Traversa
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.